Patents by Inventor Christopher Roland Wellaway

Christopher Roland Wellaway has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20230040299
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: August 25, 2022
    Publication date: February 9, 2023
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
    Patent number: 11478478
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: October 25, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20210046073
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: January 7, 2020
    Publication date: February 18, 2021
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • Benzoimidazole derivatives as PAD4 inhibitors
    Patent number: 10815218
    Abstract: Compounds of formula (I): wherein X, Y, R1 and R3-R11 are as herein defined, and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: October 27, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Dominique Amans, Stephen John Atkinson, Michael David Barker, Matthew Campbell, Hawa Diallo, Clement Douault, Neil Stuart Garton, John Liddle, Jessica Fanny Renaux, Robert John Sheppard, Ann Louise Walker, Christopher Roland Wellaway, David Matthew Wilson
  • BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS
    Publication number: 20200095227
    Abstract: Compounds of formula (I): wherein X, Y, R1 and R3-R11 are as herein defined, and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
    Type: Application
    Filed: July 18, 2019
    Publication date: March 26, 2020
    Inventors: Dominique AMANS, Stephen John ATKINSON, Michael David BARKER, Matthew CAMPBELL, Hawa DIALLO, Clement DOUAULT, Neil Stuart GARTON, John LIDDLE, Jessica Fanny RENAUX, Robert John SHEPPARD, Ann Louise WALKER, Christopher Roland WELLAWAY, David Matthew WILSON
  • 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
    Patent number: 10583139
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: March 10, 2020
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • Benzoimidazole derivatives as PAD4 inhibitors
    Patent number: 10407407
    Abstract: Compounds of formula (I): wherein X, Y, R1 and R3-R11 are as herein defined, and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: September 10, 2019
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Dominique Amans, Stephen John Atkinson, Michael David Barker, Matthew Campbell, Hawa Diallo, Clement Douault, Neil Stuart Garton, John Liddle, Jessica Fanny Renaux, Robert John Sheppard, Ann Louise Walker, Christopher Roland Wellaway, David Matthew Wilson
  • 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20180303831
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: June 25, 2018
    Publication date: October 25, 2018
    Inventors: Dominique AMANS, Stephen John ATKINSON, Lee Andrew HARRISON, David Jonathan HIRST, Robert Peter LAW, Matthew LINDON, Alexander PRESTON, Jonathan Thomas SEAL, Christopher Roland WELLAWAY
  • BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS
    Publication number: 20180297983
    Abstract: Compounds of formula (I): wherein X, Y, R1 and R3-R11 are as herein defined, and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
    Type: Application
    Filed: May 19, 2016
    Publication date: October 18, 2018
    Inventors: Dominique Amans, Stephen John Atkinson, Michael David Barker, Matthew Campbell, Hawa Diallo, Clement Douault, Neil Stuart Garton, John Liddle, Jessica Fanny Renaux, Robert John Sheppard, Ann Louise Walker, Christopher Roland Wellaway, David Matthew Wilson
  • Tetrahydroquinoline derivatives as bromodomain inhibitors
    Patent number: 10059699
    Abstract: The present invention relates to specific novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy as bromodomain inhibitors.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: August 28, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Stephen John Atkinson, David Jonathan Hirst, Philip G. Humphreys, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
    Patent number: 10034881
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: July 31, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • TETRAHYDROQUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS
    Publication number: 20170298047
    Abstract: The present invention relates to specific novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy as bromodomain inhibitors.
    Type: Application
    Filed: September 9, 2015
    Publication date: October 19, 2017
    Inventors: Stephen John ATKINSON, David Jonathan HIRST, Philip G. HUMPHREYS, Matthew J. LINDON, Alexander G. PRESTON, Jonathan Thomas SEAL, Christopher Roland WELLAWAY
  • 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20170189401
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: March 23, 2017
    Publication date: July 6, 2017
    Inventors: Dominique AMANS, Stephen John ATKINSON, Lee Andrew HARRISON, David Jonathan HIRST, Robert Peter LAW, Matthew LINDON, Alexander PRESTON, Jonathan Thomas SEAL, Christopher Roland WELLAWAY
  • Furopyridines as bromodomain inhibitors
    Patent number: 9670221
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 6, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Dominique Amans, Paul Bamborough, Michael David Barker, Rino Antonio Bit, John Alexander Brown, Matthew Campbell, Neil Stuart Garton, Matthew J. Lindon, Tracy Jane Shipley, Natalie Hope Theodoulou, Christopher Roland Wellaway, Susan Marie Westaway
  • Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors
    Patent number: 9663533
    Abstract: Thienopyridone compounds of formula (I): or a salt thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: May 30, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Dominique Amans, Paul Bamborough, Rino Antonio Bit, John Alexander Brown, Matthew Campbell, Matthew John Lindon, Tracy Jane Shipley, Natalie Hope Theodoulou, Christopher Roland Wellaway, Susan Marie Westaway
  • 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
    Patent number: 9637456
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 2, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS
    Publication number: 20160297832
    Abstract: Thienopyridone compounds of formula (I): or a salt thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
    Type: Application
    Filed: November 12, 2013
    Publication date: October 13, 2016
    Inventors: Dominique AMANS, Paul BAMBOROUGH, Rino Antonio BIT, John Alexander BROWN, Matthew CAMPBELL, Matthew John LINDON, Tracy Jane SHIPLEY, Natalie Hope THEODOULOU, Christopher Roland WELLAWAY, Susan Marie WESTAWAY
  • 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20160016908
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 21, 2016
    Applicant: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Dominique AMANS, Stephen John ATKINSON, Lee Andrew HARRISON, David Jonathan HIRST, Robert Peter LAW, Matthew LINDON, Alexander PRESTON, Jonathan Thomas SEAL, Christopher Roland WELLAWAY
  • FUROPYRIDINES AS BROMODOMAIN INHIBITORS
    Publication number: 20160016966
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 21, 2016
    Inventors: Dominique AMANS, Paul BAMBOROUGH, Michael David BARKER, Rino Antonio BIT, John Alexander BROWN, Matthew CAMPBELL, Neil Stuart GARTON, Matthew J. LINDON, Tracy Jane SHIPLEY, Natalie Hope THEODOULOU, Christopher Roland WELLAWAY, Susan Marie WESTAWAY
  • Chemical compounds
    Patent number: 8383635
    Abstract: The invention is directed to pyrido[4,3-d]pyrimidin-5(6H)-one derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, and R4 are defined below. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: February 26, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Francis Louis Atkinson, Jeffrey Michael Axten, Maria Cichy-Knight, Michael Lee Moore, Vipulkumar Kantibhai Patel, Xinrong Tian, Christopher Roland Wellaway, Allison K. Dunn